No cold-chain storage is needed, which makes travel and daily routine considerably simpler
For the three months ended March 31, 2026, Viking reported a net loss of $158.3 million, or $1.37 per share, compared to a net loss of $45.6 million, or $0.41 per share, in the corresponding period in 2025
From a regulatory standpoint, neither retatrutide nor 5-Amino-1MQ holds a marketing authorisation in the UK
This discovery enabled the creation of a shorter, synthetically producible peptide that retains full biological activity while being more practical and cost-effective to manufacture than the full-length 44-amino acid hormone
Not only do we aim to help you achieve your desired weight, we want to create a long-term means of helping you live a healthier life